Laura Towart, Founder and CEO at Vivan Therapeutics, shared a post on LinkedIn:
“The single biggest risk factor for cancer isn’t smoking or genetics. It’s age.
At Vivan Therapeutics, we’re focused on identifying the most effective, personalized cancer treatments available today – with the potential to model other genetic diseases, including aging itself.
If age is what drives so much of the disease we treat, then extending our healthy years – our healthspan – is one of the most powerful levers we have. It’s something I care about deeply, and it’s why the biology of aging has become one of the questions I think about most: we can’t meaningfully move the needle on the diseases of later life without understanding, and influencing, how we age.
Which is why I’m excited to share Younger 2027.
It’s a six-month biological aging competition hosted by NeuroAge Therapeutics, in collaboration with TruDiagnostic, Harvard’s FaceAge, and Vero Bioscience, Inc. – built around a single question: how much younger can you get in six months?
Participants begin with at-home baseline testing, then spend six months on personalized health optimization while tracking measurable changes in their biological age. There’s a live kickoff in San Francisco on January 11-12, 2027, bringing together scientists, clinicians, innovators, and leading companies from across the longevity field, and a live finale in November 2027 to celebrate progress and recognize the winners.
Vivan Therapeutics is proud to be a partner. Our network is eligible for 10% off registration with code VIVAN10 – or register through the link below and the discount is applied automatically.”
Other articles featuring Laura Towart on OncoDaily.